Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study

INTRODUCTION: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as reported in the IMbrave150 trial. When tumor shrinkage is obtained, achieving complete response (CR) is possible in many c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudo, Masatoshi, Aoki, Tomoko, Ueshima, Kazuomi, Tsuchiya, Kaoru, Morita, Masahiro, Chishina, Hirokazu, Takita, Masahiro, Hagiwara, Satoru, Minami, Yasunori, Ida, Hiroshi, Nishida, Naoshi, Ogawa, Chikara, Tomonari, Tetsu, Nakamura, Noriaki, Kuroda, Hidekatsu, Takebe, Atsushi, Takeyama, Yoshifumi, Hidaka, Masaaki, Eguchi, Susumu, Chan, Stephen L, Kurosaki, Masayuki, Izumi, Namiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603621/
https://www.ncbi.nlm.nih.gov/pubmed/37901197
http://dx.doi.org/10.1159/000529574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603621/
https://www.ncbi.nlm.nih.gov/pubmed/37901197
http://dx.doi.org/10.1159/000529574

Ejemplares similares